相似文献
1
SARS-CoV-2 vaccinations in children and adolescents with rheumatic diseases.
Rheumatology (Oxford). 2022 Nov 2;61(11):4229-4231. doi: 10.1093/rheumatology/keac431.
2
The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review.
Front Immunol. 2022 Jul 4;13:919979. doi: 10.3389/fimmu.2022.919979. eCollection 2022.
3
Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists.
Int J Rheum Dis. 2021 Jun;24(6):746-757. doi: 10.1111/1756-185X.14107. Epub 2021 May 10.
4
Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases.
Rheumatology (Oxford). 2022 Nov 2;61(11):4472-4481. doi: 10.1093/rheumatology/keac105.
5
Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.
RMD Open. 2021 Feb;7(1). doi: 10.1136/rmdopen-2020-001553.
6
Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.
Int J Rheum Dis. 2022 Mar;25(3):353-363. doi: 10.1111/1756-185X.14279. Epub 2022 Jan 3.
7
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021 Aug;80(8):1100-1101. doi: 10.1136/annrheumdis-2021-220231. Epub 2021 Mar 19.
8
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
Rheumatology (Oxford). 2022 Nov 2;61(11):4263-4272. doi: 10.1093/rheumatology/keac103.
9
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.
10
Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'.
Ann Rheum Dis. 2021 Oct;80(10):e168. doi: 10.1136/annrheumdis-2021-220586. Epub 2021 May 7.
引用本文的文献
1
Interferon-γ Release Assay in the Assessment of Cellular Immunity-A Single-Centre Experience with mRNA SARS-CoV-2 Vaccine in Patients with Juvenile Idiopathic Arthritis.
J Clin Med. 2024 Apr 25;13(9):2523. doi: 10.3390/jcm13092523.
2
Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis.
Eur J Pediatr. 2023 Sep;182(9):4271-4284. doi: 10.1007/s00431-023-05080-3. Epub 2023 Jul 13.
3
High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey.
Rheumatol Int. 2023 Sep;43(9):1637-1649. doi: 10.1007/s00296-023-05344-z. Epub 2023 Jun 14.
Zotero 插件